TRCT
HQL

Tower Research Capital (TRC)’s abrdn Life Sciences Investors HQL Stock Holding History

Tower Research Capital (TRC)’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5
Closed – – 6256
2022
Q1 		$0 Buy
+5
New +$86 ﹤0.01% 6278
2021
Q4 		– Sell
-27
Closed -$1K – 6319
2021
Q3 		$1K Buy
+27
New +$578 ﹤0.01% 5483
2018
Q1 		– Sell
-98
Closed -$2K – 3504
2017
Q4 		$2K Sell
98
-842
-90% -$16.9K ﹤0.01% 3206
2017
Q3 		$20K Buy
+940
New +$20K ﹤0.01% 2729
2017
Q1 		– Sell
-4
Closed – – 3417
2016
Q4 		$0 Buy
+4
New +$70 ﹤0.01% 4064
2016
Q1 		– Sell
-44
Closed -$1K – 4475
2015
Q4 		$1K Buy
+44
New +$1.09K ﹤0.01% 4084
2014
Q3 		– Sell
-2,285
Closed -$47K – 4597
2014
Q2 		$47K Buy
2,285
+1,527
+201% +$32.1K 0.01% 1333
2014
Q1 		$16K Sell
758
-548
-42% -$12.2K ﹤0.01% 2110
2013
Q4 		$27K Buy
1,306
+1,207
+1,219% +$23.4K ﹤0.01% 1994
2013
Q3 		$2K Sell
99
-540
-85% -$10.3K ﹤0.01% 4107
2013
Q2 		$11K Buy
+639
New +$11.5K ﹤0.01% 2269

Other funds holding HQL

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Tower Research Capital (TRC)'s HQL Position: Q2 2022 in Review

Tower Research Capital (TRC) sold out of abrdn Life Sciences Investors (HQL) in Q2 2022, closing a stake of 5 shares.

Tower Research Capital (TRC) first reported a position in HQL in Q2 2013 and held it in 11 quarters. The position peaked at $47K in Q2 2014. 65 funds tracked by Wall St. Rank hold HQL as of Q2 2022.

  • Tower Research Capital (TRC) reported no remaining abrdn Life Sciences Investors position as of Q2 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 5 abrdn Life Sciences Investors shares in Q2 2022.
  • Tower Research Capital (TRC) first reported a position in abrdn Life Sciences Investors in Q2 2013 and held it in 11 quarters.
  • Tower Research Capital (TRC)'s abrdn Life Sciences Investors position peaked at $47K in Q2 2014.
  • 65 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2022, filed 15 Aug 2022.